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“Money makes the world go around.” We all know the truth in 
this line from the movie “Cabaret”, but in the field of alterna-
tive methods we talk about ethics, scientific progress, politics, 
animal welfare or consumer and environmental safety but rarely 
about money. In this series of articles, we have occasionally 
touched on issues that are difficult to separate from economic as-
pects. Most obviously, the article on globalisation (Bottini et al., 
2007) showed the resonance between a major economic trend 
and recent developments in the field of alternative methods. 
Most recently, the articles on cosmetics and food safety testing 
in this series included aspects of regulation and economic im-
pact (Hartung, 2008b; Hartung and Koeter, 2008). last but not 
least, the article on animal experimentation (Hartung, 2008a) 
touched on the economic implications of animal testing. Now, 
we would like to expand on the economic forces influencing the 
field of alternative methods. This requires a review of the major 
industries regulated by animal testing, differences between the 
nations, functions of animal testing in the economic cycle, alter-
native methods as a market, and costs of limitations of current 
practices and economic forces, which might force change.
Alfred A. Knopf stated “An economist is a man who states 
the obvious in terms of the incomprehensible” and John Ken-
neth Galbraith said “Economics is extremely useful as a form of 
employment for economists”. By combining our scientific and 
legal/economical expertise, the authors aim to formulate some 
considerations that are not completely obvious and to express 
them comprehensibly. As always, we encourage comments and 
replies to see whether this so far largely neglected topic delivers 
helpful insights.
Consideration 1: The “regulated communities” 
relying on animal testing are heterogeneous
The first step towards understanding the economic mechanisms 
of animal testing is to analyse which industrial sectors use ani-
mal testing and to what extent. this assessment omits animal 
experimentation for basic research, i.e. 33% of all animal use 
(european Commission, 2007). However, to some extent, ba-
sic research will follow industrial needs and priorities mainly 
via research funding. Some opportunities for improvement in 
this area have been discussed previously (Gruber and Hartung, 
2004). Here, we will focus mainly on regulatory testing (23.3% 
of all animal use (european Commission, 2007), i.e. 8% for 
toxicology and safety assessments and 15.3% for veterinary and 
human medicine products safety), i.e. testing of substances and 
products to comply with legal regulations stipulated by govern-
ment authorities, and animal-based research for the develop-
ment of industrial products (31% of all animal use; european 
Commission, 2007). table 1 summarises the size of the respec-
Tab. 1: Industry size, number of new substances and animal use by industry sector
 Total EU industry % world market New substances per year Animal use in 2005
 sale (b€)   (number, % of all animals)
Pharmaceuticals 484 28% 12 6,090,000 (50%)
• toxicology    • 490,000 (4%)
• vaccines • 8.6 • 89% • 1 • 1,850,000 (15%)
• R&D    • 3,750,000 (31%)
Cosmetics 63 50% 400* 5,600* (0.05%)
Food 600 29% n.a. 500,000# (4%)
• additives • 5 • 29% • 10 • 37,000 (0.3%)
Chemicals 563 35% 300 90,000 (0.7%)
Plant protection products 8.6 27% 8# 90,000 (0.7%)
n.a. = not applicable; sources in text plus EU 2005 animal use statistics (European Commission, 2007).
* see (Hartung, 2008b) for estimate on new substances, which are mainly food ingredients and chemicals already tested for other purposes or  
by supplying industry; # see (Hartung and Koeter, 2008) for estimate of animal numbers (mainly shellfish toxin testing)
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7,322 substances in active R&D (2005), remarkably higher 
than the number finally arriving on the market. A consider-
able number (8-30%) of drug candidates fail because of safety 
problems in humans (Kola and landis, 2004) in the clinical 
phase of evaluation despite having passed the entire toxico-
logical programme. Many of these are certainly minor haz-
ards, like nausea or a transient increase in liver enzymes, but 
we also do not assess the major chronic effects at this stage. 
Novel agent discovery strategies such as high-through-put 
screening or computer-aided drug design have obviously 
not impacted here in a positive way. It must be discussed to 
which extent precautionary animal testing impacts on these 
numbers (see below), i.e. that the considerably large propor-
tion of false-positive results gained in some notorious animal 
tests sacrifices too many substances at rather late (expensive) 
stages of development.
c) the small number of new pharmaceuticals introduced to mar-
ket carries enormous costs of on average 1.059 b€ to develop 
one drug within typically 10-13 years. 1 in 5-10,000 tested 
substances is marketed (250 go to preclinical development; 10 
continue to clinical development). Only 3 out of 10 marketed 
substances bring in enough revenue to surpass their develop-
ment costs. 26 b€ are spent for drug R&D in the eU (2007). 
this situation is increasingly unhealthy: too many diseases 
are awaiting (better) therapies for us to afford such an inef-
ficient machinery. Of course, the majority of the money is 
spent on clinical research, but animal tests make their con-
tribution, both with regard to costs and time to market and, 
more importantly, when wrong decisions on the efficacy and 
safety of lead substances are taken based on the animal tests 
performed in the R&D process. A critical reassessment of this 
too often unquestioned building block of the R&D strategy is 
more than timely.
d) A large part of the difference between the number of new 
substances introduced in the eU and US in made up by bio-
pharmaceuticals (today these are mostly recombinant human 
proteins and humanised antibodies): 1,600 eU companies 
with 33,000 employees investing 3 b€ in R&D make 9 b€ 
revenue; 1,500 US companies with 146,000 employees in-
vesting 18 b€ in R&D make 44 b€ revenue (eFPIA citing 
ernst & Young, 2007). With about half of the newly marketed 
substances being biopharmaceuticals, these actually represent 
the strongest incentive for moving away from animal testing, 
since a human protein cannot reasonably be tested in animals, 
as argued elsewhere (Hartung, 2008a; Hartung, 2009).
e) the situation is reversed for vaccines, where the eU harbours 
89% of world vaccine production (2006) worth 9.7 b€, but the 
US represents 50% of the sales market (eU: 32%). Notably, 
vaccines are (at least with regard to the traditional products, 
i.e. live, attenuated, whole cell/virus and toxoid vaccines) 
most demanding with regard to animal testing: these prod-
ucts often still require continuous efficacy and safety testing 
in animals, accounting for 15.3% of all animal use in europe 
2005. Different from synthetic chemicals or gene technology-
tive industries in europe and their share of the world market, 
estimated numbers of new substances introduced on the market 
per year as well as animal use numbers.
1.1. Pharmaceuticals
Finding new medicines for human disease and ensuring their 
safety for man is certainly the area in which animal use is best 
justifiable. In line, medical research uses a large part of all ex-
perimental animals, i.e. about 50%. this corresponds with the 
enormous size of this world market: OeCD Health Data (2005) 
totals spending on pharmaceuticals at 1-2% of the gross domes-
tic product (GDP), representing 10-20% of health care costs in 
industrialised countries. Global pharmaceutical revenues are 
expected to surpass 547 b€1 in 2009 (the US market had the 
largest share with 191-198 b€ in 2008 according to IMS Health 
(http://www.imshealth.com/)).
In europe, eFPIA (european Federation of Pharmaceutical 
Industries and Associations, http://www.efpia.org/) represents 
2,200 companies with 196 b€ retail sales on the world market. 
Eight of the top-20 companies (largest world-wide: Pfizer >> 
Glaxo-Smith-Kline > Sanofi-Aventis = Novartis, http://www.
researchwikis.com/) are located in the eU.
tens of thousands of pharmaceutical substances and prepa-
rations are in use, however, these prompt little further animal 
testing. Only astonishingly few new, original substances enter 
the world market every year: on average 10 to 15; IMS Health 
counted 57 new substances from 2000-2004 in the eU and 70 in 
the US. this represents a considerable slow-down compared to 
the nineties, where new substances in the eU totalled 89 from 
1995-1999; and 88 from 1990-1994. this is remarkable in a 
number of respects:
a) It shows that many substances are entering the US but not the 
European market. This is certainly in first place due to the 
size of this market (world sales of pharmaceuticals 2006: 54% 
North and South America, 28% europe, 19% Asia, http://
www.researchwikis.com/), but to understand why after all the 
efforts spent companies decide not to market a new product 
world-wide, we need to understand that this is mainly due to 
the significantly higher sales prices for new products in the 
US and the risk of market pressures forcing lower prices there 
if cheaper markets are being served elsewhere. the US alone 
makes up 46% of world sales (eU: 31%), but, more impor-
tantly, the US is responsible for 65% of sales of new medi-
cines (eU: 24%, Japan: 4%) according to eFPIA. We will 
discuss the impact of the delayed introduction of innovative 
medicines at a later stage; europe needs to stay alert here.
b) the evident decrease in substances making it to market is 
not due to lower R&D spending (in europe R&D 26 b€, 
107,000 scientists and in total 643,000 jobs, according to eF-
PIA). Part of the problem is the merging of major companies 
with subsequent reduction of the joint product pipeline. The 
main problem, however, is the so-called attrition rate, i.e. the 
number of substances failing in R&D – IMS Health counts 
1 Financial figures are given in € or million / billion € (m€/b€), using a conversion rate of 1.5 to the US $ where necessary.
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are SMes with <5 employees, around 50% of turnover, 62% of 
workers). On the same occasion H. G. Aleman (FIAB, the Span-
ish Food and Drinks Federation) estimated the number of euro-
pean companies at 309,700 companies (cited source: CIAA data 
& tReNDS, 2007) with a total turnover of 870 b€. the top-15 
eU retailers record a turnover of 532.7 b€ per year (source: 
CIAA citing Veraart Research, 2006).
Regarding animal testing, the approximately 5,000 food ad-
ditives used, with global sales of 16.9 b€ (2007), are most rel-
evant, and Kraft is the largest individual company. the market 
for food additives in Western europe, estimated at 3.3 b€/year, 
grows on average by 4.3% per year (Chemical Week Article, 1st 
March 2000). Notably, in China 1,500 companies produce 3.25 
million tons of food additives for the global market every year. 
However, as discussed previously (Hartung and Koeter, 2008), 
the introduction of new food additives is rather rare; only about 
10 substances per year. 
1.4 Chemicals
the european trade association CeFIC (european Chemical 
Industry Council, http://www.cefic.be/) estimates the chemicals 
world market at 1.6 trillion € (europe 563 b€, eU-252 467 b€, 
NAFtA, i.e. North American Free trade Agreement including 
United States, Canada, and Mexico, 417 b€). 10 of the top-20 
companies are based in the EU (BASF > Dow = Exxon > Bay-
er = Shell = INEOS > Sinopec = Dupont = Total). This sector 
of european industry has 1.2 million employees, one third in 
26,000 SMes. Remarkably, 38 b€ trade surplus (2005) of this 
industry represents one quarter of all EU trade surplus.
The figures characterising this industry have often been pre-
sented in the context of the ReACH legislation (Hartung, 2009): 
27,000 european companies, an estimated 140,000 commercial 
chemicals, a little more than 100,000 registered as existing 
chemicals before September 1981, 30,000 of these estimated 
to fall under the 2006 ReACH legislation with a production or 
sales volume of more than one tonne per year. the entry of new 
chemicals into the market (so far with a threshold of 100kg pro-
duction/sale) over the last few years was about 200-300 per year 
(or about 5,000 since 1981). 
General chemicals are produced by 8,530 enterprises in the 
eU-27 in 2005, employing 574,000 people and producing an 
added value of 64 b€ (eurostat, 2008).
the area of chemicals is dominated by the ReACH (Registra-
tion, evaluation, Authorisation and Restriction of Chemicals) 
legislation (European Commission, 2006), the consequences 
of which are difficult to predict, both with regard to animal 
testing requirements and forced exchange of substances. The 
latter may be prompted by the foreseen restriction and authori-
sation of substances newly identified as harmful, as well as by 
changes of use of chemicals based on findings not requiring 
these more drastic regulatory measures. Not to forget, many 
substances might be abandoned by their producers to avoid 
the testing and registration effort for low profit substances. 
derived vaccines, these products may differ between lots and 
require not only a package of animal data for the initial reg-
istration but regular tests, which belong to the most severe 
animal tests performed routinely.
1.2 Cosmetics
We addressed this area in an earlier article of this series (Har-
tung, 2008b) and included details on the cosmetics market 
there. the european trade association COlIPA (the european 
Cosmetic Association, http://www.colipa.eu/) totals annual eU 
sales at 58 b€ with a 4% growth rate. the eU Directorate Gen-
eral (DG) Enterprise quotes somewhat higher sales of cosmetic 
products (in 2006) at € 63 billion, almost half the global total 
(http://ec.europa.eu/enterprise/e_i/news/article_6940_en.htm).
Five billion cosmetic items are sold per year in the eU by 
2,000 companies, with 150,000 employees plus 350,000 em-
ployees in the respective retail business. the world market is 
estimated by others (http://www.researchwikis.com/) to rise to 
300 b€ (2010), with a strong growth rate of 4-7% in the US. 
The largest companies are L’Oréal (14 b€) >> Avon (5.3 b€) > 
estée lauder (4 b€).
the market is extremely different from the pharmaceuti-
cal market: More than 20,000 new products with an estimated 
400 new substances enter the market world-wide every year. 
About 15,000 substances are used in cosmetics products, as can 
be deduced from the list of “ingredient names” (the european 
Commission has recently launched “CosIng” http://ec.europa.
eu/enterprise/cosmetics/cosing/, an online database of the ingre-
dients used in cosmetic products). The finished products have 
extremely short shelf-lives, with 25% of turnover made with 
products that have been on the market for less than 6 months. 
1.3 Food
Again we refer the reader to an earlier article in this series (Har-
tung and Koeter, 2008), which already gives some summaries, 
especially regarding the european food industry, complement-
ed here by some US and global figures. Processed food sales 
worldwide add up to approximately 2.1 trillion € (2004). In the 
US, consumers spend approximately 670 b€ annually on food, 
(Plunkett Research, 2007) or nearly 10 percent of GDP. More 
than 16.5 million people are employed in the food industry 
(including retail and restaurants) (http://en.wikipedia.org/wiki/
Food_industry). 50% of top-50 companies are based in the US 
(http://www.researchwikis.com/), the biggest being Unilever 
and Kraft. the sector represents one sixth of US industrial ac-
tivities with 1.5 million direct employees (2002). 
the CIAA (Confederation of the food and drink industries 
of the eU, http://www.ciaa.be) totals the eU market in 2002 at 
600 b€. the eU DG enterprise on food industry (CIAA meet-
ing, July 2008) pointed to the strong role of small/medium en-
terprises (SMes, less than 250 employees) in the food sector 
(99% of all enterprises, 70 to 80% of wholesaling companies 
2 EU-25 refers to the 25 member states of the EU as of 1st May 2004, while EU-15 is used to describe the 
EU of the “old” 15 member states and EU-27 the EU after the enlargement of 1st January 2007.
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only make up a small proportion (<1-4%) of the several mil-
lion cases of occupational injuries and ill health in agricultural 
workers worldwide. this still prompts very extensive data re-
quirements for the toxicity evaluation of PPP: EPA states that 
on average a toxicity package worth 19 million US$ is available 
for each of the 900 registered PPP. this is a wealth of informa-
tion increasingly exploited for the development and evaluation 
of novel approaches, e.g. in the US ePA toxCast programme 
(http://www.epa.gov/ncct/toxcast/index.html). 
1.6 Geographical spread
Different economic areas compete with their regulations by im-
posing their standards on their trade partners. trade volumes 
are thus of key interest, as already discussed for pharmaceuti-
cals, where the predominance of the US sales market for new 
medicines makes FDA standards dominant in pharmaceutical 
industry. However, general trade, e.g. household products, cos-
metics, food or chemicals, is much more dominated by europe. 
For example, while europe imports about 50% of its food, the 
US produces 90% nationally. World trade reflects the strong 
role of Europe as shown in the global figures in b€ (Le Monde 
diplomatique, 2006): Europe (2687 b€)  >>  Asia (1592 b€) 
>  North America (883 b€)  >>  Gulf States (260 b€), South 
America (184 b€), Russia/eastern europe (177 b€), Africa 
(155 b€). this means that europe has a share of 45% of the 
world trade. We have seen that its share of regulated industries 
of the world market, however, is around 28%, with the notable 
exceptions of vaccines (89%), cosmetics (50%) and chemicals 
(35%), the latter claiming to contribute one fourth to the trade 
surplus of the eU. For cosmetics, with the biggest eU states’ 
markets maturing, eU companies are increasingly turning to ex-
ports. eU exports of cosmetic products have grown strongly in 
recent years. The trade balance is firmly in the EU’s favour, with 
exports almost four times the value of imports. the big eU-
based companies make almost one-third of their sales on foreign 
markets, and SMes also export 10 to 20% of their production to 
non-eU countries.
It is obvious that europe has a strong interest in harmonising 
regulation and easing international trade. Here it is remarkable 
that exactly those industries that contribute most to world trade 
surplus are now being forced to introduce alternative approaches 
to animal testing (by the 7th amendment of the cosmetics direc-
tive and by ReACH). this dominance on the world market will 
have strong implications for spreading these novel approaches 
to other economic areas, as discussed later.
Consideration 2: Animal testing is a market, and a 
global industry leads to global animal use
taylor and co-workers recently performed a very interest-
ing analysis of animal use in different countries (taylor et al., 
2008). When plotting their estimates per country against GDP, 
i. e. the most common measure of national income and output 
for a given country’s economy (GDP = consumption + gross in-
vestment + government spending + (exports − imports)), we see 
this will prompt innovation, but will likely also increase the 
number of new chemicals entering the market in the medium 
term.
1.5 Plant protection products
the world market of 2004 for plant protection products (PPP) 
was estimated at 32.5 b€ (http://www.researchwikis.com/) with 
45% pesticides, 28% insecticides and 22% fungicides. Mostly 
chemical companies also sell PPP: BASF (11% of their sales), 
Bayer (20%), Dow (9%), Dupont (16%). It takes an average of 
ten years and an investment of about 200 m€ to develop and 
register a new pesticide.
In the eU (From farm to fork statistics, eurostat, 2006), 
353,000 tonnes of PPP (1999, eU-15) worth 8.6 b€ (2003, eU-
25) compared to 15.6 million tons of fertiliser (1999, eU-15) 
worth 10.7 b€ (2003, eU-25) were sold. Most recent sales in 
the eU (2007 according to european Crop Protection Associa-
tion, http://www.ecpa.be/) totalled 7 b€ with roughly 3b€ each 
for herbicides and fungicides as well as 1 b€ for insecticides 
(annual report 2007-2008, http://www.ecpa.eu/website/page.
asp?cust=3&lang=en&mi=4). The volume of products used in 
the eU-15 increased from 2002 to 2007 by 73.4% up to 270,714 
tonnes (due in particular to a 12% increase in herbicide vol-
umes). In the eU-15 and Switzerland, staff numbers stand at a 
total of nearly 23,800 employees. 
the number of PPP is estimated to be around 1,000 with only 
about 8 new substances (but many more formulations of estab-
lished substances) entering the world market per year. european 
Union legislation (Directive 91/414/eeC) has already resulted 
in a reduction of the available portfolio of pesticides in europe 
by more than 55% over the last decade (530 of the 952 crop 
protection products that existed previously have been elimi-
nated). Some scientist fear that from a resistance management 
point of view, the crop protection products portfolio in europe 
has already been very seriously impaired by the ongoing eU 
re-registration process (http://www.irac-online.org/documents/
ljubljana_pressrelease.pdf). A further significant reduction in 
compounds is to be expected from the current revision proc-
ess of Directive 91/414/eeC. this will likely result in increased 
needs for new substances and might impact on R&D in this field 
in the medium term.
A key difference to other chemical products is that PPP need to 
be toxic. While biological activity is otherwise only desired for 
pharmaceuticals, this implies that toxicity also to man is much 
more of a concern for PPP. Something that is for example toxic 
to insects has a certain likelihood of being toxic to humans. the 
World Health Organisation and the UN environment Program 
estimated that each year 3 million workers in agriculture in the 
developing world experience severe poisoning from pesticides, 
about 18,000 of whom die (Wikipedia citing Miller Gt (2004), 
Sustaining the earth, 6th edition. thompson learning, Inc. Pa-
cific Grove, California. Chapter 9, Pages 211-216). As many as 
25 million workers in developing countries may suffer mild pes-
ticide poisoning yearly (Jeyaratnam, 1990). But these estimates 
are rather old and do not stand up to all criticism. More recently 
(Lichfield, 2005), it was concluded that pesticide poisonings 
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(Fig. 1) an almost perfect correlation (r2 = 0.99). The message is 
simple: economy needs animals – almost exactly one animal per 
million $ GDP – and there are no major deviations for the major 
economies. europe has about 30% of world GDP, and we can 
use this to translate the european data to other economies.
What does regulatory safety testing of synthetic substances 
cost? Fleischer (2007) carried out a survey on costs and capaci-
ties of laboratories running safety assessments in 9 countries. 
Since this is a competitive market with a stable situation of de-
mand and offer of test capacities (which might change soon in 
the context of ReACH, see below), the average prices can be 
used as a solid estimate of test costs, also for in-house tests in 
some companies. Applying these costs and the animal numbers 
per test to the eU statistics on animal use in 2005 results in an 
estimation of the testing costs (tab. 2): this rough estimate sug-
gests that toxicity and safety assessments in europe cost 620 m€ 
per year. this is based on several assumptions, e.g. that contract 
research laboratories (CRl) cost about the same as in-house 
testing, that the prices for Good laboratory Practice (GlP) com-
pliant testing used are not too different from non-GlP-studies 
(typically 20% additional costs are given as a sound estimate), 
and that studies grouped here under a certain heading reflect 
the costs of the respective guideline test. However, the overall 
result seems reasonable with regard to rank order when compar-
Fig. 1: Correlation of GDP with animal use
Correlation of gross domestic product (GDP) in trillion US$ 
for 52 countries (Wikipedia, 2008) in 2007 for members of the 
International Monetary Fund with animal use estimates (Taylor 
et al., 2008) in million animals per country. A linear regression 
analysis of the log-transformed data was carried out.   
Tab. 2: Estimate of costs of toxicological testing and safety evaluations in Europe
Animal test Animal number per test Costs per test [€] Animal use in 2005 Total cost [k€]
In vivo skin irritation 2 650 12,243 3,978
In vivo eye irritation 2.7 1,343 4,208 2,093
Skin sensitisation 23 3,959 43,889 7,554
Further mutagenicity 64 18,898 35,483 10,477
Acute oral tox 8 1,474 237,110 43,687
Acute inhalation tox 20 11,734 21,556 12,646
Acute dermal tox 10 2,011 43,110 8,669
Short-term repeated dose 50 49,390 129,333 127,755
Sub-chronic tox 32 115,656 55,934 202,159
Long-term repeated tox 160 372,000 55,934 130,047
Developmental tox screening 560 54,597 8,099 789
Developmental tox study 300 63,100 32,398 6,814
Two-generation reprotox 3,200 327,975 63,311 6,489
Carcinogenicity 400 780,357 42,024 81,984
Short-term fish 42 4,193 11,408 1,139
Long-term fish tox 108 9,319 634 54
BioAccumulation (fish) 70 40,330 634 365
Total   1,026,286 619,699
Animal use numbers for 2005 (European Commission, 2007) were interpreted by applying costs and animal numbers of guideline tests. Some tests are 
grouped in the 2005 animal use statistics; the following rough assumptions were used to split these: acute and subacute tests (Acute oral tox 55%, Acute 
inhalation tox 5%, Acute dermal tox 10%, Short-term repeated dose 30%); subchronic and chronic tests (Sub-chronic tox 50%, Long-term repeated tox 50%), 
developmental toxicity (Developmental Tox screening 20%, Developmental Tox study 80%) and toxicity to aquatic vertebrates (Short-term fish 80%, Long-
term fish tox 5% and BioAccumulation (fish) 5%). 
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Consideration 3: The extent of animal test based 
regulation differs between industrial sectors
In the then 25 member states of the eU (eU-25), 12.1 million 
animals were used in experiments in 2005 (european Com-
mission, 2007). Considering only the eU-15, the total number 
of animals used had increased in 2005 by 339,279 compared 
to the previous report from 2002, representing an increase 
of 3.1%. the number of animals used for toxicological and 
other safety evaluations has dropped from about 9.9% (data 
of 2002) to 8% of all animal use in europe in 2005. But in 
total numbers, the decrease is only minor, i.e. from 1,066,047 
to 1,026,286 animals.
table 3 compares the different industries with regard to the 
extent of animal use for regulation of the sector, also based on 
the regulatory testing per new substance or per b€ of turnover 
of the industrial sector (tab. 2). Clearly, the search for new 
drugs consumes the most animals, obviously owing to the 
many substances tested but abandoned on the way. Chemi-
cals require little testing, most of them receive just the basic 
set (“six-pack”: skin and eye irritation, skin corrosion, muta-
genicity, sensitisation, acute toxicity testing) of testing. Food 
additives and PPP consume considerably more animals, both 
because of higher testing demands and for substances never 
making it to the market.
Consideration 4: Recent European legislation for 
cosmetics and chemicals changes the business of 
animal tests and alternative methods
In recent years, europe has taken over the role of global pace-
maker for consumer and environmental protection legislation 
from the US. the respective legislation that uses animal tests 
for implementation and regulation (especially ReACH, the 
7th amendment of the cosmetics regulation, the general food 
legislation, several revisions for food additives and genetically 
modified food and feed, as well as the current revision of the 
PPP directive) deserves some thoughts here.
ing them to the turnover of CRl calculated below. Interestingly, 
this estimate would suggest that most resources are spent on 
(sub-)chronic testing (332 m€), (sub-)acute testing (127 m€) 
and carcinogenicity testing (82 m€). extrapolating these data 
to a global scale, a multiplication factor of 3-4 based on overall 
animal numbers and share of world market of industries seems 
realistic, suggesting that 2-2.5 b€ are spent for toxicological 
testing per year worldwide.
It is difficult to find an estimation of the number of people 
working in animal testing. A report (lantra, 2006) acknowl-
edging the “sensitive nature” of this information estimates 285 
businesses with 3,400 people in the UK. the latter number is 
substantiated by about 2,200 members of the key organisation, 
the Institute of Animal technology. their organisational break-
down is: government organisations (10%), research council 
(6%), medical research (17%), commercial breeder (3%), uni-
versity (32%), commercial pharmaceutical company (16%) and 
other (15%).
According to the lantra report, 14,000 personal license hold-
ers for animal experimentation (i.e. mainly scientists) carried 
out experiments on 2.72 million animals in 2003. there is no 
reason to assume that in other countries significantly less or 
more personnel are required for conducting animal experimen-
tation. thus, more than 60,000 people might be involved in 
animal testing in europe, or about 300,000 worldwide, based 
on the estimates of taylor et al. (2008). Similarly, the 3,400 
professionals working in the UK on animals for experimental 
purposes can be extrapolated to 14,600 in the eU and 73,000 
world-wide. 
An important part of the animal testing market is made up 
by CRls. A comparison of top competitors (2007 sales revenue 
and market share) is given by Wikinvest (http://www.wikinvest.
com/stock/Charles_River_laboratories_International_(CRl)): 
Covance 1.167 b€ (28.5%), Charles River labs 757 m€ (8.5%), 
MPI Research 75 m€ (1.84%), Harlan Sprague Dawley 34 m€ 
(0.83%), Huntingdon life Sciences Research 15 m€ (0.36%) 
and others (privately owned) with an estimated 50% market 
share. thus, this represents an industry with 4.1 b€ total sales. 
In conclusion, animal experimentation represents a relevant 
industrial branch in its own right.
Tab. 3: Regulatory animal testing relative to the introduction of new substances or annual turnover in Europe
Sector Animals / new substance Animals / b€ turnover
Pharmaceuticals 41,000 (including R&D 353,000) 4,800
Cosmetics n.a. 89
Food additives 3,700 7,400  (all food 833)
Chemicals 300 159
PPP 11,300 10,465
Data in Table 1 on EU animal use are given relative to the number of new substances introduced per year or the EU revenues in this sector. For pharmaceuti-
cals both figures based on regulatory tests only and in brackets those including animal use for agent discovery are given. For cosmetics, which use new 
substances tested for other purposes or by other industries, numbers are not applicable (n.a.). Since animal testing for food is mainly for food additives (with 
the most important exception of shellfish control not falling into the categories of this table), data are restricted to this field, but the proportion relative to all 
food turnover is given in brackets.
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4.1 The REACH effort
the Registration, evaluation, Authorisation and Restriction of 
Chemicals (ReACH) legislation is the largest investment into 
consumer safety ever. ReACH has been described extensively 
elsewhere (http://echa.europa.eu/home_en.asp, http://ecb.jrc.
ec.europa.eu/reach/). It is an unprecedented effort and will have 
percussions on the global chemical industry. Notably, there are 
efforts both in Japan and California to set up similar approaches. 
the US HPV (high production volume) chemical programme is 
not comparable with regard to the number of chemicals (4,000) 
and data requirements (most are dealt with by read-across, (Q)
SAR (quantitative structure activity relationship), and existing 
data) as well as the voluntary nature of the programme.
The first interesting aspect is the cost of this programme. 
Fleischer (Fleischer, 2007) has calculated the average price 
of the test packages for ReACH according to tonnage levels. 
Combining this information with the estimates of substances 
falling into the different tonnage categories, results in the fig-
ures in table 4.
this means that data worth almost 9 b€ will be collected. 
How much of this data is already available, how new testing 
strategies might impact on the costs, how many substances will 
be abandoned, and whether the estimates on substance num-
bers are correct, are questions that deserve a separate, in-depth 
analysis. the best analysis so far dates back to 2004 (Pedersen 
et al., 2003). that analysis does not sum up the testing costs 
generated if all tests really have to be carried out from scratch, 
but examines different scenarios which suggest about 1.6 b€ 
(maximum 2.4 b€) of direct testing costs, based on extremely 
optimistic assumptions about available data, waiving of testing 
and acceptance of (Q)SAR analysis. For example, the authors 
assume that only 7.3% of the two-generation reproductive tox-
icity studies (which in most scenarios account for >50% of the 
costs and >70% of the animal use of REACH) will have to be 
carried out, although the test guidelines published by the agency 
and analyses on data availability (Bremer et al., 2007) give no 
indication that test omissions will be possible. Noteworthy, the 
figure of 1.6 b€ does not include the cost of administering the 
registrations within the companies, the registration fees of the 
agency, additional testing to challenge/verify results, costs for 
substitution of substances, etc. It is fair to assume that all these 
contributions will significantly increase the overall costs. The 
higher figures are corroborated by estimates made by BASF 
(personal communications around 2005), where about 2,700 
substances falling under ReACH are expected to produce ad-
ditional costs of 600 m€ (and require about 150 additional 
personnel). Noteworthy, already in 2001 the MRC in leicester 
(MRC-IeH, 2001) calculated 8.7 b€ of costs and 50 million an-
imals. They identified a lack of testing facilities, finding only 16 
suitable CRl in europe and also warned that the actual number 
of substances requiring testing might be as high as 65,000. In 
fact, eCHA has published a list of pre-registered substances on 
its website (http://echa.europa.eu/news/press_en.asp): the list 
contains about 150,000 substances which were pre-registered 
by 65,000 companies between 1 June and 1 December 2008. 
thus, all estimates on costs and animal numbers will need to be 
updated once this list has been reviewed.
ReACH plans for the last preliminary safety assessments to 
be submitted in 2019. Since the lowest tonnage levels do not 
require authorisation of proposed animal experiments, this 
would theoretically mean that the work on the existing chemi-
cals should be completed about two years later. thus, over the 
next decade, on average more than one b€ of costs per year will 
be imposed on the chemical industry. this might be considered 
insubstantial given the 600 b€ annual turnover of this industry 
in Europe, but profit margins are generally considered to be nar-
row and competition, especially for large-volume chemicals, is 
fierce, especially with some Asian producers.
test capacity is a big issue. What total capacity is available 
today, which part can be used by chemical industry and which 
capacities can be created? let us attempt a naive estimation: 
today, about 300 new substances are handled per year. ReACH 
will require roughly 3,000 substances to be tested every year; 
thus, the testing capacity for chemicals needs to be increased 
ten-fold. Since testing of chemicals makes up 10% of all ani-
mal use for toxicology (and toxicology 10% of all animal use), 
this roughly means doubling toxicological testing capacity. 
However, this calculation immediately falls short, because the 
nature of tests required will change dramatically: Almost all 
new chemicals so far fall under tonnage levels between 100 kg 
and 10 tonnes, with rather limited information requirements. 
In contrast, the most relevant testing demands for ReACH 
originate from a completely different set of information re-
quirements, i.e. reproductive and chronic toxicity testing. The 
most dramatic example is the most animal demanding test 
(two-generation reproductive toxicity testing with 3,200 ani-
mals per substance) – over the last 26 years about 3 chemical 
substances per year required such tests. REACH is expected 
Tab. 4: The value of information requirements in REACH
Tonnage level Expected number of substances Average cost for full test set [€] Total costs [billion €]
     1-10 t/a 20,000 56,360 1.13
   10-100 t/a 4,600 279,838 1.29
100-1000 t/a 2,900 799,562 2.32
 > 1.000 t/a 2,600 1,582,616 4.12
      Total 30,100  8.86
Average test costs (Fleischer, 2007) were multiplied with the expected number of substances falling under REACH in the different tonnage levels.
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Consideration 5: Animal testing serves different 
functions in the product life cycle
5.1 Agent discovery
this refers mainly to biologically active agents, i.e. drugs and 
PPP. Animal testing has lost a lot of its importance for agent dis-
covery: Search strategies with higher through-put are typically 
being employed – logical given the figures on the number of 
substances that must be tested to identify a lead compound. the 
overall reduction of animal use by probably two thirds over the 
last three decades mainly reflects this change (beside the reduc-
tion of duplicate testing). today, a molecular understanding of 
the pathophysiology and the desired mode of action generally 
allow the use of non-animal methods, with late stage confirma-
tory testing in a disease model in case of drug development. 
5.2 Safety assessments and liability
Safety evaluations are typically defined by regulatory require-
ments. this is certainly telling: Shouldn’t every product have a 
certain profile of reasonable test requirements, which address 
for example the “excess pharmacology” of the agent and chemi-
cal class specific concerns? Shouldn’t the company spending a 
billion € on the development of a drug know it very well and be 
able to choose the right set of tests? Instead, a tick-box approach 
is followed and only a standard list of tests is run. this has sev-
eral advantages for both the notifier and the regulator:
– A standard set of information means few difficulties in inter-
pretation (comfort zone of the regulator).
– Omitting a certain test might imply responsibility if effects 
are found later.
– the production of the dataset can be timed easily because a 
standard battery is run.
– Defence against liability claims is easy since the state of the 
art has been applied.
However, animal use might be considerably reduced if infor-
mation requirements had to be justified towards the regulator 
and liability stayed with the producer. ReACH is moving into 
this direction by requesting a test plan to be approved by the 
agency for higher tonnage level chemicals and shifting the bur-
den of proof (liability) to the industry. It will be interesting to 
see whether this new approach works out and can be transferred 
to other sectors.
5.3 Marketing with “animal welfare”
the success of the Body Shop with their aggressive “Against 
animal testing” strategy is the key example here (http://
en.wikipedia.org/wiki/the_Body_Shop): Signage posted in 
the Body Shop locations reads, “Our products are not tested 
on animals, never have been and never will be.” However, the 
Body Shop website expands this to acknowledge that “the fact 
is that almost all cosmetics ingredients have been animal test-
ed by somebody at some time for someone. So no cosmetics 
company can claim that its ingredients have never been animal 
tested.” It is not clear what the actual value of this statement 
is (http://www.mcspotlight.org/beyond/companies/bodyshop.
to require about 5,500 such tests (Höfer et al., 2004) in total, 
or more than 50 per year.
If we assume that the costs estimated by Fleischer for the 
1-10 tonne package reflect current average testing demands for 
new chemicals, annual testing costs of 16.9 m€ result, while 
REACH will require about 880 m€, a 52-fold increase (assum-
ing that test costs reflect the use of capacities and resources of 
the laboratories, which should be so in a competitive market 
where the animals themselves are a minor cost factor). Since 
there will be peaks in testing demands, this figure might be even 
larger in some years. 
Outsourcing of animal testing to countries like India and Chi-
na represents an important consideration here. this is possible 
in principle, if the requested quality standards (Good Labora-
tory Practice, GlP) are met. At this moment, the lack of ac-
creditation and inclusion of these countries into the respective 
OeCD processes largely prohibits such outsourcing, but this 
might change soon. this will lead to changes in costs and will 
impact on the animal numbers used in europe (though not on 
the global total). the extent of such lateral shifts that will oc-
cur between geographical regions is not clear. From an animal 
welfare point of view, this is clearly not desirable, i.e. export-
ing testing to countries with lower animal welfare standards. 
An interesting amendment to REACH could be to request data 
obtained for submission to adhere to european animal welfare 
standards independent of the country in which the tests were 
performed.
4.2 The 7th amendment of the cosmetics directive
Some key aspects have been discussed in an earlier part of this 
series (Hartung, 2008b). Some remarkable features of this leg-
islation are:
– the request for alternative methods, reinforced by deadlines 
even in the absence of (accepted) alternatives – with bans 
starting in 2009 and 2013 on the marketing of products con-
taining substances tested on animals in europe; it is very unu-
sual that an industry is expected to develop the tests for their 
regulation itself and to reinforce this with a marketing ban 
although no danger to consumers etc. is expected.
– the global outreach – according to current interpretation, the 
ban extends to tests carried out outside of europe (even when 
required there by law).
– the lack of regulatory implementation – it is not clear who 
will control and prosecute (reinforce the marketing ban).
– the lack of prosecution so far – already since September 2004 
the directive bans the marketing of products if ingredients 
have been tested on animals although alternatives have been 
accepted or if finished products have been tested on animals. 
We are not aware of any compliance check, but products have 
obviously been put on the european and in parallel onto other 
markets that require end-product testing since this deadline.
003-016-AltexHartung.indd   10 14.2.2009   16:16:05 Uhr
Bottini and Hartung
Altex 26, 1/09 11
Consideration 7: The limitations of animal tests 
have economic consequences
Using a technology with limitations comes at a price. there are 
mechanisms at work to cross out the limitations and their price. 
In the following we shall make some estimates of the latter.
7.1 Black swans
We have discussed the impact of prevalence on toxicity test-
ing earlier (Hoffmann and Hartung, 2005). the concept is easy: 
when looking for a hazard, we need to consider whether it is 
a frequent or a rare one. If it is frequent, even methods with a 
large uncertainty will do well. But if we are looking for some-
thing rare, the error rate becomes relevant, even for reasonably 
good methods. to give an example, we typically accept an error 
rate of 5% in science (in statistical tests of significance). If we 
are looking for a hazard that is expected in 5% of the substanc-
es tested, we will end up with roughly as many correct posi-
tive as false-positive results. this means half of the substances 
tested that get a verdict of “guilty” are in fact innocent. If we 
go lower than 5% prevalence (which is more realistic), if we 
employ methods with larger limitations (which is more realistic) 
or when we apply precautionary approaches (which is what we 
typically do), we further worsen the equation, ending up with 
even more false-positive results.
this might be acceptable for new substances without an estab-
lished economic value, but when ReACH now applies the very 
same strategy to the most valuable substances in the chemical 
industry, the sacrifice might be more than substantial.
the concept has recently been put forward much more el-
egantly by Nassim N. taleb in his wonderful book “the black 
swan” (Taleb, 2007). He defines black swan events by the 
“triplet: rarity, extreme impact and retrospective (though not 
prospective) predictability”. Which toxicologist does not imme-
diately think of thalidomide/ContergantM, lipobaytM or Vi-
oxxtM? taleb claims “what is surprising is not the magnitude 
of our forecast errors, but our absence of awareness of it”. In 
toxicology, we often take the absence of evidence of a hazard 
as evidence of its absence. this is when the black swan hurts. 
the compensatory mechanisms are precautionary methodolo-
gies; we presume higher frequencies of hazards to allow the ap-
plication of Gaussian type statistics and reasoning. However, 
this only creates the belief that we have covered most of the 
putative hazards, and finding so many harmless or borderline 
events belittles the real threat. taleb acknowledges an enormous 
problem: “True, our knowledge does grow, but it is threatened 
by greater increases in confidence, which makes our increase 
in knowledge at the same time an increase in confusion, igno-
rance, and conceit.” 
7.2 Precautionary testing
the precautionary principle goes back to the German concept 
of a “Vorsorge-Prinzip” (cautionary principle), although there is 
no generally accepted definition (Gollier and Treich, 2003; Lof-
stedt et al., 2002). In general, it means that in case of uncertainty 
html): According to market leader l’Oréal no cosmetic product 
has been tested on animals in europe since 1989, but all (most 
probably including those sold in the Body Shop) make use of 
ingredients tested on animals by others, especially the supply 
industry. However, it represents a model for a marketing strat-
egy which has put competitors under pressure. the Body Shop 
experienced rapid growth (expanding at 50% per year). the suc-
cess of the brand (which is since 2006 part of l’Oréal) demon-
strates the value put on animal welfare by consumers, in line 
with results of recent european surveys showing an extremely 
high importance given by citizens to animal welfare issues (A 
2005 eUROBAROMeteR survey recorded that 82% of eU 
citizens believe we have a duty “to protect the rights of animals 
whatever the cost”. A 2006 eU Commission survey showed that 
93% of respondents believe more needs to be done to improve 
the welfare/protection of experimental animals). It might be ap-
propriate to think about a protected “not tested on animals” la-
bel with the respective standards.
5.4 Trade barriers
Different safety testing standards are barriers to free trade. We 
have earlier discussed the important role of OeCD test guide-
lines in harmonising test requirements (Bottini et al., 2007). 
However, we must not forget that there are important markets 
outside the OeCD. Countries like Brasil, China and Russia, to 
name only some, represent not only exporters but, with an in-
creasing upper class and high-tech industry, also importers of 
european products. thus their reliance on traditional methods 
is an obstacle to the introduction of any novel approach – even 
if accepted in the OeCD. the only possible solution is the in-
sistence on the novel method (e.g. by deleting the traditional 
one from the catalogue of test guidelines as done so far only 
for the classic lD50 test, OeCD tG 400) and the international 
collaboration and harmonisation with all major (emerging) mar-
kets. Since we represent far more interesting export markets for 
them, chances are that we may also be able to export our stand-
ards to them (see below).
Consideration 6: Alternative methods are a  
market in their own right
We have shown earlier that animal testing is a multi-b€ market 
– alternatives have the potential to take over this market. In fact, 
some alternative methods, such as pregnancy tests or pyrogenic-
ity testing (limulus test), have reached three-digit m€ sales. es-
pecially ReACH raises hopes that certain novel methodologies 
will find a market, which will smooth their standardisation and 
commercialisation. this improves their availability and inter-
national use. to some extent, the market of alternative methods 
is also expanding owing to the silent substitution of services by 
contract research laboratories (mutagenicity, skin and eye corro-
sion/irritation, fish egg test etc.). Still, development, validation 
and regulatory acceptance take too long (more than 10 years) 
to suit the needs of biotech companies for return of investment. 
there is room for improvement.
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years of life expectancy and, according to these estimates, NCe 
launches account for 40% of these, i.e. 0.79 years. He calcu-
lated that the average annual increase in the world population 
age resulting from one NCe launch is 0.056 years (2.93 weeks). 
What impact might five times more substances moving ahead 
in clinical development have, if the false-positive results of the 
cancer bioassay and the two-generation reproductive toxicity 
study could be avoided?
Lichtenberg confirmed his data with a study of differences in 
drug launch times in the federal states of the US (lichtenberg, 
2007). Here he even found a 63% contribution to increase in 
life expectancy by new drugs (2.43 years from 1982 to 2004). 
In another study (lichtenberg, 2005b), he showed the impact of 
changing from the prescription of old (pre-1970) to new drugs 
on mortality in 800,000 people of the Medicaid programme in 
the first half of 2000. He calculated that the actual mortality rate 
of 3.5% for the following 2 years would have been 4.4% if all 
had received pre-1970 drugs. 
this argument shows that a precautionary test approach 
resulting in an unnecessary reduction of drug candidates or 
pressure to change to lead compounds with a less favourable 
pharmacological profile directly affects society, not only the 
prosperity of the individual company. Similar calculations for 
other areas of regulation are not available, but we have been 
warned of the true costs of a precautionary chemicals regulation 
(Durodie, 2003).
7.3 Technology mismatch
The question we must address is: can products of the early 21st 
century be regulated using methods of the early 20th century. 
Sure, some things never change, because they are basic and 
meet the need, such as measuring length with a meter. But even 
this required numerous improvements on the definition of and 
international agreement on a “gold standard”. the purpose of 
animal tests, however, is rather complex and changing, and we 
are far from international gold standards. the closest we have 
come are international test guidelines, with known and unknown 
limitations (Hartung, 2008a).
We have earlier commented on the problem of fixing these 
international guidelines in time (Bottini et al., 2007): it takes a 
decade to generate one, but currently it takes the same length 
of time to make any significant changes; at the same time, the 
range of regulated products is changing with an ever accelerated 
pace. Recent examples include cellular therapies, gene technol-
ogies, nanotechnologies. this turnover forces us to regularly re-
view the way we do things, to allow the evolution of toxicology 
(Hartung and leist, 2008; leist et al., 2008). However, we lack 
a mechanism to drive this change. We might argue that the vali-
dation of alternative approaches is this mechanism, a means to 
introduce innovative methods to replace the old ones. the key 
problem, however, is that as long as we consider the status quo 
to be the gold standard without any limitations, we cannot re-
ally move ahead and improve. the best we can do is to achieve 
an approximation with a perceived compromise, because 100% 
identical results are usually not achieved. We have therefore pro-
posed (Hoffmann and Hartung, 2006) a mechanism to systemat-
a worst case scenario is assumed and decisions are taken on its 
basis. In toxicology, the concept is inherent in the creation of 
over-sensitive test models that minimise false-negatives (missed 
toxicants) by accepting false-positives (wrong allegations of 
toxicity). High doses, use of the most sensitive species, testing 
in several species and sensitive endpoints (low thresholds for 
toxicity categories) are the typical tools employed to render a 
test sensitive. this follows the same precautionary logic. 
the precautionary principle has been disputed from various 
sides, e.g. the Wall Street Journal wrote in an editorial (Gollier 
and treich, 2003): the precautionary principle “…is an envi-
ronmentalist neologism, invoked to trump scientific evidence 
and move directly to banning things they don’t like – biotech, 
wireless technology, hydrocarbon emissions”. Stephen Breyer 
(1993, Breaking the vicious circle: toward effective regulation) 
has attributed the problem to “a public hungry for worst-case 
scenarios to inflame its fears, and to a class of risk assessors 
all too eager to fuel this fire”. Such extreme criticism has been 
addressed (Resnik, 2003), and the conclusion reached, i.e. that 
the principle is scientific if threats are credible and the precau-
tionary measures are reasonable, is consistent with an evidence-
based approach to policy-making. 
If taken too far, the precautionary principle may indeed inhib-
it economic development (Gollier and treich, 2003). One key 
problem is the “opportunity cost of precautionary measures” 
(Majone, 2002): the attempt to control poorly understood, 
low-level risks necessarily uses up resources that in many cas-
es could be directed more effectively towards the reduction of 
well-known, large-scale risks. But there is also a further type of 
opportunity cost to consider, i.e. abandoning a certain substance 
or restricting a technology impairs opportunities for business 
and to serve societal needs. An evident example is a therapy 
that does not make it to the market/patient because precaution-
ary tests suggest a toxicity problem. It is difficult to estimate the 
danger posed from such a result. We have tried elsewhere to esti-
mate the false-positive rate of prominent toxicity tests (Hartung, 
2009): to identify the estimated 5% carcinogenic chemicals, for 
example, the cancer bioassay is employed, which finds 53% of 
all substances positive; to identify 2-3% reproductive toxicants, 
the two-generation test in two species is employed, which finds 
about 60% of substances positive. If these were independent 
tests, they alone would together only let 19% of substances pass 
without assigning them a carcinogenic or reproductive toxicant 
label, a sure elimination from further development unless they 
are being developed as chemotherapy for cancer. But the toxi-
cological toolbox is much larger… 
lichtenberg (lichtenberg, 2005a) calculated the impact of 
the launch of new chemical entities (NCe), i.e. structurally new 
drugs, on the steady increase in human longevity: He used the 
IMS Health Drug launch database, which has tracked product 
introductions worldwide since 1982 and contained 165,000 
records in August 2001. From this he evaluated for each country 
and therapeutic area the actual number of ingredients launched. 
this was matched to the WHO Mortality database using 11 
broad disease categories. He showed that launches of NCes 
have a strong positive impact on the probability of survival. 
Between 1986 and 2000, the overall population gained 1.96 
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World trade Organisation (WtO) created in 1995, ruled against 
the higher protective standards of the US. It will be extremely 
important to see whether the animal protection standards of the 
7th amendment of the cosmetics directive will lead to a simi-
lar WtO ruling. this could have happened already, because 
since September 2004 end-product testing of cosmetics should 
preclude marketing in europe, as should the use of ingredients 
tested on animals where alternatives were available. However, 
products are still being entered into world markets that have 
conflicting regulations, without any known legal challenge. Per-
haps this will change after the deadline of March 2009. Chal-
lenges will likely arise from animal welfare NGOs (as we have 
seen in the field of environmental legislations) instead of in 
form of national prosecution.
Independent of any cost/benefit analysis, the attractiveness 
of the european cosmetics market has instigated discussions 
on the convergence of legislation in many countries. If europe 
can demonstrate the feasibility of its novel approach, others are 
likely to follow. this would follow the argument of Vogel, who 
does not see free trade impairing higher national standards but 
favouring their export, because:
– producers who operate in many markets have a strong interest 
in making national product standards more similar in order to 
reduce their production costs.
– the compatibility between trade expansion and protective 
regulation has to do with the structure and authority of inter-
national institutions.
– the increase in regulation has not been more disruptive to 
trade [due to the link] with increasing international … treaties 
and agreements.
We will see whether this is wishful thinking or will in fact lead 
to the globalisation of animal protection standards.
8.2 Refining research techniques
life science is one of the fastest growing disciplines: its knowl-
edge base is said to double every 5 to 7 years. especially the 
key technologies of alternative approaches, i.e. cell culture and 
computer-based modelling, have undergone dramatic develop-
ments, often referred to as the informatics and biotech revolu-
tion. Science aims to stay on the cutting-edge with many mech-
anisms, such as peer-review, forcing the scientists to stay up 
to date. the backlog of overdue method renewal in regulatory 
toxicology is most remarkable, since hardly any scientific field 
continues to use experimental set-ups developed more than 40 
years ago. This reflects the absence of scientific control mecha-
nisms, such as publication, peer-review, repeat experiments and 
competitive funding in this field.
However, the development of (bio-)informatics and biotech-
nologies and their commercialisation creates new momentum. 
Companies trying to develop their markets challenge established 
approaches. they aim to take a share of the agent discovery area 
(most open to innovation), basic research, as well as the regu-
latory testing market (most resistant to change). If the above 
estimates are realistic, we are talking about markets worth sev-
eral b€ per year in europe alone. Many start-ups targeted new 
therapies first but then discovered that developing methods for 
ically review the status quo methodology on the basis of the best 
evidence available at a given time, using the most objective and 
transparent processes. Borrowing from the field of clinical med-
icine and their evidence-based medicine movement, the sugges-
tion was put forward to create an evidence-based toxicology. It 
is remarkable that in less than three years, the idea has flour-
ished with the proceedings of the first international forum held 
in 2007 being published (Griesinger et al., 2009; http://www.
ebtox.org), a symposium being held at the last eurotox in 2008, 
and a special issue on the topic being prepared in the journal 
“toxicology”. Furthermore, one of the authors (tH) was privi-
leged to be appointed the first chair for evidence-based toxicol-
ogy at the beginning of 2009 (Doerenkamp-Zbinden chair for 
evidence-based toxicology in the Bloomberg School of Public 
Health at Johns Hopkins University, Baltimore, US). Since this 
university also hosts the Cochrane center for evidence-based 
medicine for the US, an optimal synergy with the far more es-
tablished eBM movement can be hoped for.
Consideration 8: Economic forces could improve  
the situation
the common european market was the driver for the progres-
sive european animal welfare legislation. In principle the eU 
has no mandate for animal welfare. It is remarkable that the Di-
rective 86/609/eeC on the welfare of laboratory animals was 
only created because it was deemed that different animal welfare 
standards made for unfair conditions for entering the common 
market in different Member States. In principal, the legislation 
does thus not cover basic research, but most Member States up-
dated this in one act when translating it into national law.
But it is not only the political will and the forces of the com-
mon market which have helped to raise the importance of ani-
mal welfare. We see in general that ethical aspects of business 
are receiving increasing attention. ethical treatment of employ-
ees, consideration of different cultures, marketing with ethical 
arguments and social responsibility are increasingly integral in 
the culture of individual companies.
8.1 The positive effect of globalisation on 
spreading animal welfare standards
We have discussed the prospects of globalisation on the interna-
tional implementation of alternative approaches earlier (Bottini 
et al., 2007). Here, we will limit ourselves to reflecting on the 
similarity in arguments made by David Vogel with regard to 
environmental standards (Vogel, 1995): He argues that although 
trade liberalisation has undermined national regulatory sover-
eignty, it also globalises regulatory policy-making by exporting 
standards as well as goods. the primary challenge is whether 
a country should be allowed to restrict the sale of a product on 
the basis of how it was produced outside its legal jurisdiction. 
In case of environmental legislation the classical dispute was 
about the US ban on tuna from Mexico which did not fulfill US 
standards for dolphin protection. In 1991, the GAtt (General 
Agreement on tariffs and trade of 1947), the predecessor of the 
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cosmetics directive have already been discussed here extensive-
ly. the credibility of such legislations depends strongly on the 
accompanying measures, such as research funding and creation 
of institutions for the validation and agencies for the implemen-
tation of novel approaches. especially european funding (with 
about 25 m€ by the eU and 19 m€ by Member State organisa-
tions) is not matched by other economic regions. Considering 
the market opportunities as well as the regulatory needs sum-
marised earlier, this appears to be a good investment, actually 
a rather small investment given the annual turnover in this field 
and the enormous impact better regulation could have.
8.6 Positive effect of regulation on innovation
the MIt-economist Michael e. Porter has most prominently 
put forward the hypothesis that regulations stimulate innovation 
(Porter, 1991). the concept has been challenged for chemical 
industry and ReACH (Frohwein and Hansjurgens, 2005), but 
only with regard to the substitution of substances. However, a 
principal goal of ReACH (article 1) is also the development of 
new alternative methods; here, the “Porter effect” might spring 
into action, just as the 7th amendment to the cosmetics direc-
tive had a positive impact (Hartung, 2008b). the information 
demands of ReACH focus precisely on toxicological endpoints 
that are complementary to those of the 7th amendment or, more 
precisely, those only required for its later deadline in 2013, 
which are – with the notable exception of repeated dose toxicity 
– only rarely required for cosmetic ingredients. Thus, together, 
the two legislations create pressure to drive innovation in the 
entire spectrum of toxicological endpoints.
8.7 EPAA as a public/private partnership
We have discussed earlier the public-private partnership ePAA 
(the european Partnership on Alternative Approaches to Ani-
mal testing, http://ec.europa.eu/enterprise/epaa/index_en.htm) 
(Hartung, 2008b). A public-private partnership is a government 
service or private business venture funded and operated through 
a partnership of government with one or more private sector 
companies. ePAA was launched in November 2005 during the 
“europe Goes Alternative” conference as a joint initiative be-
tween the Commission services, more than 30 companies and 7 
trade federations. It is based on a commitment to the 3R’s Dec-
laration (reduce, refine & replace animal testing). In general, a 
partnership is a type of business entity, in which partners share 
with each other the profits or losses of the business undertaking 
in which all have invested. thus, the name might be somewhat 
misleading, since ePAA sees itself more as a collaboration plat-
form and major budgets have not been created. It enjoys the full-
hearted support of the initiating Commissioners Gunter Verheu-
gen (enterprise and Industry), ”The agreement underlines that 
the EU is in the lead for animal protection. We do not only wish 
to reduce animal testing, but also want to bring it to an end in 
the long run. Anyway, alternative testing methods are innova-
tions, which benefit the competitiveness of European industry” 
and Janez Potočnik (Sciences and Research): “The agreement 
with different industry sectors is a major step forward in mak-
alternative testing can possibly be quicker or provide additional 
revenue: prominent examples include artificial skin originally 
developed for burn patients, stem cell technologies originally 
targeting transplant indications, or novel liver cells often de-
veloped for patients with liver failure. With fresh ideas, profes-
sional solutions and the clout to drive their methods to success, 
especially small/medium enterprises have changed the field of 
alternative approaches over the last few years.
8.3 Increasing standards of animal welfare
Animal welfare standards are rising continuously, interestingly 
not only because of animal welfare considerations, but because 
their impact on the quality of results is increasingly recognised. 
This includes a clear definition of the experimental animal (de-
fined inbred and outbred strains), exclusion of confounders such 
as latent infections (specified pathogen-free, SPF) and using 
sufficiently large and enriched cage environments. The positive 
effect of these measures on experimental design and outcome 
has been documented on various occasions. the various pro-
fessional organisations, but also funding bodies and journals 
requesting certain standards to be explicitly adhered to, have 
helped a lot toward implementing and developing them further. 
last but not least, the animal welfare directive 86/609/eeC has 
helped a lot to raise and harmonise animal welfare in the eU, 
and expectations are high that the current revision will further 
augment this. 
8.4 Activity of animal welfare groups
Similar to the environmental field, animal welfare is character-
ised by large activist groups that are aligned internationally and 
are increasingly accepted as stakeholders in legislative and reg-
ulatory processes. Noteworthy, not only by creating awareness 
and shaping public opinion as well as lobbying to politicians 
have they promoted animal welfare standards and legislation, 
but they also play an important role in the process as watch-dogs 
for their implementation. It is likely that, similar to the envi-
ronmental field, especially the European Court of Justice will 
further influence the interpretation and application of legislative 
standards via cases brought forward by such organisations. this 
is especially important since the eU has no executive forces for 
the implementation and the monitoring of legal provisions.
8.5 Increasing demand for regulation
europe has taken over the role of pacemaker for legislative 
standards for the environment. Recent initiatives in the chemi-
cals, food and plant protection product area give evidence of 
this role. For animal welfare standards, the leading role of eU 
legislation is obvious from the 1986 legislation binding all 
Member States and, as a horizontal legislation, also impact-
ing on various other political frameworks. In contrast, the US 
animal welfare legislation dates back to 1967 and desperately 
awaits an update. 
the two key legislations impacting on the development of 
alternative methods, i.e. ReACH and the 7th amendment of the 
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of the european Parliament and of the Council of 18 Decem-
ber 2006 concerning the Registration, evaluation, Authorisa-
tion and Restriction of Chemicals (ReACH), establishing a 
european Chemicals Agency, amending Directive 1999/45/
eC and repealing Council Regulation (eeC) No 793/93 and 
Commission Regulation (eC) No 1488/94 as well as Council 
Directive 76/769/eeC and Commission Directives 91/155/
eeC, 93/67/eeC, 93/105/eC and 2000/21/eC. Official Jour-
nal of the European Union L 396/1, 1-849.
european Commission (2007). Fifth Report from the Commis-
sion to the Council and the european Parliament on the Sta-
tistics on the number of animals used for experimental and 
other scientific purposes in the member states of the European 
Union COM/2007/675 final. http://ec.europa.eu/environment/
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eurostat (2006). Food: From farm to fork statistics – statisti-
cal pocketbook. http://ec.europa.eu/food/resources/publica-
tions_en.htm
eurostat (2008). the manufacture of basic chemicals. Eurostat 
Statistics in focus 58.
Fleischer, B. (2007). testing costs and testing capacity accord-
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zerland. J. Business Chem. 4, 96-114.
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ple. J. Risk Uncertainty 27, 77-103.
Griesinger, C., Hoffmann, S., Kinsner-Ovaskainen, A. et al. 
(2009). Foundations of an evidence-Based toxicology. Pro-
ceedings of the First International Forum towards evidence-
Based toxicology. Conference Centre Spazio Villa erba, 
Como, Italy. 15−18 October 2007. Human Exp. Toxicol. (in 
press). 
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perimentation in basic research. ALTEX 21 Suppl. 1, 3-31.
Hartung, t (2009). toxicology kissed awake. Nature (in press). 
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ing validated alternative methods available. We will support the 
partnership by increasing our efforts to support research, devel-
opment and evaluation of alternative testing methods under the 
new Research Framework Programme.” It is thus an interesting 
new type of collaboration between the regulating and the regu-
lated community. From what we have observed so far, ePAA 
has changed the way first competing companies within one sec-
tor, then different industrial sectors and lastly industry and the 
Commission talk to each other and agree on action points to 
jointly solve the challenge of reducing and finally overcoming 
animal testing.
Conclusions
The endeavour to consider animal testing not under scientific or 
ethical but business considerations reveals a number of stake-
holders with significant commercial interests who are affected 
by the ethical and scientific discussions. Although it was dif-
ficult to produce a precise picture, since many figures are not 
freely available, an interesting picture already emerges on the 
basis of estimates and extra- and intrapolations. It shows that 
major industries, trade and workforces are intimately linked to 
regulation based on animal testing. It becomes clear that this 
is more than the simple production costs or imposed barriers, 
but that problems of the quality of current testing also have an 
impact on decision-taking and regulation of products. this un-
derstanding might help to make stakeholders more amenable to 
thinking more critically about the current procedures, the first 
step to becoming more amenable to change. Understanding how 
the status quo is impairing the economy and causing delays and 
high costs to businesses can be harnessed to a driving force to 
improve methods with the added bonus of improving animal 
welfare standards. the calculation of a possible impact on life 
expectancy of less medical progress caused by precautionary 
testing, though still somewhat premature, might still show that 
we are also talking about relevant societal effects in this discus-
sion, not only about lost business opportunities for individual 
companies.
To close, we are aware that this text represents only a first 
sketch of an analysis of the economic aspects of animal testing. 
Some perceived trends might have to be revised, but it is com-
forting that economists also see their approaches as somewhat 
limited, to cite laurence J. Peter (1919-1988): “An economist is 
an expert who will know tomorrow why the things he predicted 
yesterday didn’t happen today.” 
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